| アブストラクト | AIMS: Immune-related adverse events(irAEs) are common among cancer patients receiving dual immune checkpoint inhibitors (ICI). Cardiac adverse events rank among the most severe categories of such reactions. This study aims to investigate the characteristics and influencing factors of cardiac adverse events associated with dual ICIs. METHODS AND RESULTS: We collected data on cardiac adverse events associated to dual ICIs from the US Food and Drug Administration Adverse Event Reporting System database (FAERS), covering the period from the first quarter of 2015 to the fourth quarter of 2024. A disproportionality analysis was performed to assess the association between different dual ICIs and cardiac adverse events, and a comprehensive study was conducted to identify potential influencing factors. Cardiac adverse events accounted for 7.5% of all ICI adverse event reports in the FAERS database. Nivolumab plus ipilimumab was associated with the highest number of significant preferred term (PT) signals, while durvalumab plus tremelimumab had the highest percentage of life-threatening outcomes. The median onset time for cardiac adverse events following dual ICIs therapy was 32 days (IQR 15-77). Myositis and myasthenia gravis were the most commonly co-reported extracardiac conditions in myocarditis cases, whereas complete atrioventricular block and cardiogenic shock were the most frequently reported intracardiac complications. Older patients, males, and those with kidney cancer were at higher risk of developing cardiac adverse events. CONCLUSION: This study identified distinct associations between different dual ICIs treatment strategies and various cardiac adverse events. We further identified potential risk factors and co-reported symptoms of cardiotoxicity, which may aid in the early diagnosis and monitoring of ICI-associated cardiac adverse events. |
|---|
| 投稿者 | Xia, Huang; Shi, Lei; Luo, Shuimei; Sun, Zequn; Quan, Mengru; Xiao, Huazhen; Chen, Yu; Lin, Jing |
|---|
| 組織名 | Department of Phase I Clinical Trial Ward, Clinical Oncology School of Fujian;Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province 350000,;China.;NHC Key Laboratory of Cancer and Metabolism (Fujian Cancer Hospital), Fuzhou,;Fujian Province 350000, China.;Department of Medical Oncology, Clinical Oncology School of Fujian Medical;University, Fujian Cancer Hospital, Fuzhou, Fujian Province 350000, China.;Cancer Bio-Immunotherapy Center, Clinical Oncology School of Fujian Medical;Department of Chemistry, Fuzhou University, Fuzhou 350108, Fujian Province,;Department of Cardiology, Shengli Clinical Medical College of Fujian Medical;University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial;Hospital, East Street, Fuzhou, Fujian Province 350000, China. |
|---|
